DaVita Inc. DaVita Inc.

DaVita Inc.

DVA

Rang in Aktien #1801
DaVita Inc. specializes in delivering essential kidney dialysis treatments and... DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Aktienkurs
$186.93
Marktkapitalisierung
$11.93B
Veränderung (1 Tag)
0.06%
Veränderung (1 Jahr)
48.50%
Land
US
Handel DaVita Inc. (DVA)

Kategorie

Healthcare
Gewinn für DaVita Inc. (DVA)
Gewinn im Jun 2026 TTM: $1.47B
Laut den aktuellen Finanzberichten von DaVita Inc. betragen die aktuellen Gewinne des Unternehmens $1.47B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $1.53B, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $1.18B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von DaVita Inc. von 2000 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $1.47B 8.98%
2025 $1.35B -11.99%
2024 $1.53B 30.01%
2023 $1.18B 21.82%
2022 $966.28M -36.37%
2021 $1.52B 15.19%
2020 $1.32B 10.27%
2019 $1.20B 14.02%
2018 $1.05B -25.10%
2017 $1.40B -5.98%
2016 $1.49B 105.89%
2015 $723.14M -44.78%
2014 $1.31B 16.42%
2013 $1.12B 12.35%
2012 $1.00B 12.17%
2011 $892.67M 19.91%
2010 $744.46M -1.82%
2009 $758.22M 24.41%
2008 $609.46M -2.88%
2007 $627.52M 31.90%
2006 $475.76M 43.69%
2005 $331.10M -8.51%
2004 $361.88M 25.54%
2003 $288.27M -8.83%
2002 $316.19M 31.23%
2001 $240.94M 436.19%
2000 $44.94M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$9.87B 572.50%
US
- -
DE
$3.87B 163.32%
US
$687.82M -53.14%
SA
$1.25B -15.06%
BR